As I’ve mentioned previously, once a month the CDC presents a Public Health Grand Rounds webcast, that focuses on a single public health issue. In April of last year I gave considerable blog space to CDC Grand Rounds: Sodium Reduction.
Tuesday, May 15, 2012 1 p.m. – 2 p.m., EDT
A couple of my offerings include:
True in the 1940s, but sadly, no longer the case – Photo Credit scdhec.gov
and . . .
Here is the CDC’s announcement for today’s Grand Rounds:
Public Health Grand Rounds
This session of Grand Rounds will explore the development of antibiotic resistance in Neisseria gonorrhoeae as a growing public health concern because the United States gonorrhea control strategy relies on effective antibiotic therapy. Since antibiotics were first used for treatment of gonorrhea, N. gonorrhoeae has progressively developed resistance to the antibiotic drugs prescribed to treat it: sulfonilamides, penicillin, tetracycline, and ciprofloxacin. Currently, CDC STD treatment guidelines recommend dual therapy with a cephalosporin antibiotic (ceftriaxone is preferred) and either azithromycin or doxycycline to treat all uncomplicated gonococcal infections among adults and adolescents in the United States.
Given the ability of N. gonorrhoeae to develop antibiotic resistance, it is critical to continuously monitor gonococcal antibiotic resistance and encourage research and development of new treatment regimens for gonorrhea.
Today’s presenters include:
Edward Hook III, MD
Professor of Medicine and Epidemiology
University of Alabama, Birmingham
William Shafer, PhD
Professor of Microbiology and Immunology
Carolyn Deal, PhD
Chief, Sexually Transmitted Diseases Branch
National Institute of Allergy and Infectious Diseases
National Institutes of Health
Robert D. Kirkcaldy, MD, MPH
Centers for Disease Control and Prevention
National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention